Image-Guided Interventional Oncology Market: By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, and Other Cancers), By Clinical Use (Cancer Diagnosis, Cancer Treatment, Portal Vein Embolism, Management of Cancer Complication), By Diagnosis Method (X-Rays, CT, MRI, Ultrasound, and Fluoroscopy), By End User (Hospitals, Ambulatory Surgical Centers, and Research and Academic Centers) and Geography 

 In 2023, 772.7 (‘000) image-guided interventional procedures were performed globally to diagnose, treat, and manage different types of carcinomas. Different imaging techniques are used for procedural assistance and to improve the overall outcome. Interventional procedures are mostly preferred in carcinomas of the soft tissues such as the Liver, Breast, Lungs, Renal, and Prostate malignancies. Some other types of cancer where the use of interventional procedures is increasing are pancreatic cancer, Brain Cancer, Bone Cancer, etc.

With the increase in popularity of the minimally invasive procedure, patients and physicians prefer to go for the interventional procedure. These procedures and advanced imaging technology in infusion are revolutionizing cancer management regimens. Various imaging modalities, such as fluoroscopy, ultrasonography, computer tomography, magnetic resonance imaging, etc. are used as guidance for the proper placement of probes, precision application of energy, further clarity of procedural outcome, and treatment regimen redesigning or modification, among others.

In terms of cancer type, Image-guided interventional procedures are primarily performed in liver cancer with an overall share of 27.1% of all the procedures globally. Embolization is a standard method for treating liver carcinoma to increase the net Future Liver Remnant (FLR). Imaging Technologies such as CT-Scan, MRI, Ultrasonography, etc. are used in diagnosis, treatment and management interventional procedure. 3D imaging, Live imaging, etc. are some of the recent developments in the IGIO procedures.

In terms of Image Technology analysis, in 2023, CT has mostly used imaging technology in interventional oncological procedures owing to the detailed imaging capability, multi-planer imaging reconstructions, etc. Ultra-Sound accounts for 23.0% of all the IGIO procedures. Ultra-Sound technology is cheaper than CT and MRI and can perform on mobile. It does not require a large setup.  Recent advances show intravenous UV imaging, which will boost the rapidly developing IGIO technology.

Image Guided Interventional Oncology (IGIO) Market Key Developments:

• In June 2023, The IMAGIO consortium of clinical partners, which is supervised by Philips, has received a EUR 24 million Innovative Health Initiative (IHI) grant, in addition to resources and funds from industrial partners, according to a statement from Royal Philips. The group, which consists of about 30 partners, will utilize the cash to advance interventional oncology advances targeted at soft tissue sarcomas, lung cancer, and liver cancer to enhance clinical outcomes.
• In August 2022, Obsidio, a South Carolina-based medical device startup that invented a new viscoelastic substance for blood vessel embolization, was acquired by Boston Scientific. Obsidio's Gel Embolic Material, or GEL, is administered via the catheter and quickly adapts to the patient's vascular, establishing a barrier. It was approved by the US Food and Drug Administration in July 2022.